Provided by Tiger Fintech (Singapore) Pte. Ltd.

OptimizeRx Corporation

7.77
+0.62008.67%
Post-market: 7.800.0301+0.39%19:52 EDT
Volume:1.07M
Turnover:8.07M
Market Cap:143.13M
PE:-5.78
High:8.00
Open:7.10
Low:6.84
Close:7.15
Loading ...

Whetstone Capital Discloses 8.2% Stake in OptimizeRx, Urges Strategic Alternatives

GuruFocus.com
·
06 Feb

OptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel Nicolaus

TIPRANKS
·
13 Jan

OptimizeRx downgraded to "sector perform" by RBC amid slower growth outlook

Investing.com
·
08 Jan

OptimizeRx Cut to Sector Perform From Outperform by RBC Capital

Dow Jones
·
08 Jan

RBC Downgrades OptimizeRx to Sector Perform From Outperform, Cuts Price Target to $6 From $7

MT Newswires Live
·
08 Jan

OptimizeRx (OPRX) was downgraded to a Hold Rating at RBC Capital

TIPRANKS
·
08 Jan

OptimizeRx Price Target Maintained With a $11.00/Share by Lake Street

Dow Jones
·
25 Dec 2024

OptimizeRx Is Maintained at Buy by B. Riley Securities

Dow Jones
·
24 Dec 2024

Lake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departure

TIPRANKS
·
24 Dec 2024

B. Riley Cuts Price Target on OptimizeRx to $13 From $17, Keeps Buy Rating

MT Newswires Live
·
24 Dec 2024

Stifel Nicolaus Keeps Their Buy Rating on OptimizeRx (OPRX)

TIPRANKS
·
24 Dec 2024

OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range

MT Newswires Live
·
23 Dec 2024

OptimizeRx announces departure of CEO Febbo, appoint Silvestro as interim CEO

TIPRANKS
·
23 Dec 2024

OptimizeRx Corp: Reaffirms Its Financial Guidance for Full Year 2024

THOMSON REUTERS
·
23 Dec 2024

OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

THOMSON REUTERS
·
23 Dec 2024

OptimizeRx: Expects FY Results Will Come in at Higher End of Its Guidance Range for Revenue & Adjusted Ebitda

THOMSON REUTERS
·
23 Dec 2024